Clinical Trials for Small Cell Lung Cancer

KB707-02: a Phase 1/2 Study of Inhaled KB707 in Patients with Advanced Solid Tumor Malignancies Affecting the Lungs

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

TrialFetch AI summary: This study enrolls adults with advanced (stage 3 or 4) NSCLC or other solid tumors affecting the lungs who have progressed after, are intolerant of, or have refused standard therapy, and who have measurable lung lesions and good performance status. Treatment is with inhaled KB707, a gene therapy delivering IL-12 and IL-2 via a non-integrating HSV-1 vector to enhance local anti-tumor immunity, either as monotherapy or in combination with pembrolizumab and/or chemotherapy.

ClinicalTrials.gov ID: NCT06228326

Phase II Trial of Photon Craniospinal Irradiation for Leptomeningeal Disease Secondary to Solid Tumor Malignancy

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with leptomeningeal disease secondary to breast cancer or non-small cell lung cancer who have adequate performance status and organ function, and treats them with photon craniospinal irradiation using VMAT, an advanced conformal radiation therapy technique. All patients receive 10 fractions of CSI over 10 to 20 days to assess efficacy and safety in controlling central nervous system progression.

ClinicalTrials.gov ID: NCT06910761

A Phase II Study of Osimertinib With On-study and Post-progression Biopsy in the First Line Treatment of EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Eligible patients are adults with stage IV, EGFR inhibitor-naive NSCLC harboring sensitizing EGFR mutations (exon 19 deletion or L858R) and good performance status, who receive single-agent osimertinib, an oral third-generation, irreversible EGFR tyrosine kinase inhibitor. The study includes mandatory tumor biopsies before treatment and at progression for genomic analysis.

ClinicalTrials.gov ID: NCT03586453

A Phase 2, Open-label, Randomized Trial to Evaluate Two Dosing Regimens of Subcutaneous Formulation of Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent NSCLC

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with previously untreated metastatic or recurrent non-small cell lung cancer (NSCLC) without targetable mutations, testing two dosing regimens of subcutaneous nivolumab (a PD-1 inhibitor) in combination with intravenous ipilimumab (a CTLA-4 inhibitor) and standard chemotherapy. Patients must have measurable disease and good performance status, and those with untreated CNS metastases or active autoimmune disease are excluded.

ClinicalTrials.gov ID: NCT06946797

Open-label, Non-randomized, Multi-cohort, Phase 1b/2 Trial Investigating the Safety, Tolerability, and Antitumor Activity of STC-15 (a METTL3 Inhibitor) as a Part of Combination Therapy With Toripalimab in Participants With Selected Advanced Cancers

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with advanced or metastatic NSCLC, melanoma, endometrial cancer, or HNSCC who have progressed after standard therapies including prior anti-PD-1/L1 agents, and evaluates the combination of STC-15 (an oral METTL3 inhibitor targeting RNA methylation) plus toripalimab (anti-PD-1 antibody). Eligible patients must have measurable disease, ECOG 0–1, and no active CNS disease.

ClinicalTrials.gov ID: NCT06975293

Study of NMS-03305293, a Non-Trapping PARP1-Specific PARP Inhibitor in Relapsed Small Cell Lung Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with extensive-stage SCLC relapsing within 6 months after platinum–immunotherapy (and after tarlatamab if appropriate), up to three prior lines, receive oral NMS-03305293 (a PARP1-selective, non-trapping PARP inhibitor) continuously with temozolomide days 1–5 of 28‑day cycles. Single-arm study focuses on safety/PK and preliminary activity in this heavily pretreated population with measurable disease and ECOG 0–2.

ClinicalTrials.gov ID: NCT06931626

RAdiation comBined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (RABBIT) Study: A Phase I/II Study of AMG757 / Tarlatamab and Concurrent Radiation Therapy in Tumors With High Prevalence of DLL3

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with relapsed/refractory DLL3-expressing or DLL3-prevalent tumors (including SCLC, LCNEC, high-grade neuroendocrine tumors, and select NSCLC/other histologies) receive the DLL3-directed bispecific T‑cell engager tarlatamab plus external-beam radiation, given concurrently or sequentially depending on safety. Key risks include CRS/ICANS; includes extracranial and cranial RT cohorts with allowance for treated/stable brain mets and selected brain lesions.

ClinicalTrials.gov ID: NCT06814496

Study of Trilaciclib and Lurbinectedin in Small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with extensive-stage SCLC that has progressed after prior platinum and PD-1/PD-L1 therapy (ECOG 0–1, measurable disease) receive lurbinectedin plus trilaciclib. Lurbinectedin is a DNA-binding transcription inhibitor; trilaciclib is a transient CDK4/6 inhibitor given to protect hematopoietic stem/progenitor cells and reduce severe myelosuppression while assessing antitumor activity.

ClinicalTrials.gov ID: NCT05578326

A Single Arm Phase II Study Assessing Efficacy of Stereotactic Radiosurgery (SRS) for Brain Metastasis (BM) From Small Cell Lung Cancer (SCLC)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with histologically confirmed SCLC and up to 10 brain metastases (KPS 60–100/ECOG 0–2), without prior brain RT or leptomeningeal disease, receive stereotactic radiosurgery to all lesions. Designed to evaluate intracranial control and short-term survival (6-month OS) with focal SRS instead of whole-brain radiotherapy.

ClinicalTrials.gov ID: NCT05419076

A Randomized, Multi-Cohort Phase II Trial of Temozolomide and Atezolizumab as Second or Third Line Treatment for Small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with extensive-stage SCLC progressing after platinum-based chemoimmunotherapy (chemo-sensitive or -resistant), ECOG 0–2, measurable disease, and no prior temozolomide are randomized to atezolizumab (anti–PD-L1) plus temozolomide with either a 5-day or extended 14–21 day oral schedule. Stable, asymptomatic brain metastases are allowed; outcomes include response rate, PFS (including intracranial), OS, and safety.

ClinicalTrials.gov ID: NCT04919382